Alizyme to start Phase IIb IBS study

Alizyme (LSE:AZM) said it will start this quarter an 8-week 160-patient U.K. Phase IIb study of daily ATL-1251 renzapride to treat irritable bowel syndrome (IBS) patients suffering from mixed symptoms...